Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.

Scientific reports - 17 Jan 2022

Benoit Alexandre, Bou-Petit Elisabeth, Chou Hsiang, Lu Melissa, Guilbert Cynthia, Luo Vincent Mingyi, Assouline Sarit, Morin Ryan D, Dmitrienko Svetlana, Estrada-Tejedor Roger, Johnson Nathalie A, Mann Koren K

Abstract excerpt

Diffuse large B cell lymphoma (DLBCL) is successfully treated with combination immuno-chemotherapy, but relapse with resistant disease occurs in ~ 40% of patients. However, little is known regarding relapsed/refractory DLBCL (rrDLBCL) genetics and alternative therapies. Based on findings from other tumors, we hypothesized that RAS-MEK-ERK signaling would be upregulated in resistant tumors, potentially correlating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to MAP Kinase Signaling System

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35039569
DOI: 10.1038/s41598-021-04736-0
PMCID: PMC8764096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.PMID 35039569Read ↗

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.Semantic proximity Read ↗

Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.Semantic proximity Read ↗

Targeting pathological ERK1/2 signaling in cancer and beyondSemantic proximity Read ↗

Prognostic and immunological role of Ras-related protein Rap1b in pan-cancerSemantic proximity Read ↗

The Role of Ras-Associated Protein 1 (Rap1) in Cancer: Bad Actor or Good Player?Semantic proximity Read ↗

Function of RasGRP3 in the formation and progression of human breast cancerSemantic proximity Read ↗

Elucidating oncogenic mechanisms in human B cell malignanciesSemantic proximity Read ↗

Ras and Rap1: A tale of two GTPases.Semantic proximity Read ↗

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancerSemantic proximity Read ↗

EFNB1 level affects drug response in DLBCL cell linesSemantic proximity Read ↗

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read ↗

Novel Mutations in RASGRP1 are Associated with Immunodeficiency, Immune Dysregulation, and EBV-Induced Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.